Poly Medicure · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Chinese manufacturers circumvent anti-dumping duties by routing through ASEAN (zero import duty). Management is petitioning government for counter duties. Despite 20%+ growth guidance, competition remains fierce with cost inversion against PolyMed's domestic manufacturing.
Red Sea diversions causing shipping bottlenecks and logistics cost inflation. Demand remains intact but supply chain disruptions are delaying execution of pending orders from a region contributing 6-8% of revenue.
CTF and Pendra operating at 12-14% EBITDA margins vs group average, dragging consolidated margins. Q4 subsidiary impact was negative 2.66 crore with calendar Q1 seasonality headwinds. Analyst pressed on receivables normalization (86 days vs 68 days YoY) with management indicating FI27 will see similar DSO levels.
Despite 20% aggregate raw material cost increase and 3-5% price hikes taken, gross margin guidance of 66-68% implies 200-300 bps compression. Management acknowledged current business plan is built on $100-110 crude, leaving limited margin of safety if prices remain elevated.
